ATE442155T1 - Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids - Google Patents

Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids

Info

Publication number
ATE442155T1
ATE442155T1 AT05764629T AT05764629T ATE442155T1 AT E442155 T1 ATE442155 T1 AT E442155T1 AT 05764629 T AT05764629 T AT 05764629T AT 05764629 T AT05764629 T AT 05764629T AT E442155 T1 ATE442155 T1 AT E442155T1
Authority
AT
Austria
Prior art keywords
combination
aids
treatment
antiviral agents
hiv
Prior art date
Application number
AT05764629T
Other languages
English (en)
Inventor
Daniela Paulsen
Helga Rubsamen-Waigmann
Amar Kureishi
Gerhard Hunsmann
Christiane Stahl-Hennig
Andreas Meyerhans
Alexandra Schutz
Olaf Weber
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35115792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE442155(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Application granted granted Critical
Publication of ATE442155T1 publication Critical patent/ATE442155T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05764629T 2004-07-13 2005-07-08 Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids ATE442155T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016414 2004-07-13
PCT/EP2005/007395 WO2006005529A1 (en) 2004-07-13 2005-07-08 Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids

Publications (1)

Publication Number Publication Date
ATE442155T1 true ATE442155T1 (de) 2009-09-15

Family

ID=35115792

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05764629T ATE442155T1 (de) 2004-07-13 2005-07-08 Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids

Country Status (13)

Country Link
US (1) US8343478B2 (de)
EP (1) EP1765370B1 (de)
JP (1) JP4897677B2 (de)
CN (2) CN103800382A (de)
AT (1) ATE442155T1 (de)
BR (1) BRPI0513321B1 (de)
CA (1) CA2573204C (de)
DE (1) DE602005016552D1 (de)
DK (1) DK1765370T3 (de)
ES (1) ES2330540T3 (de)
PL (1) PL1765370T3 (de)
PT (1) PT1765370E (de)
WO (1) WO2006005529A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013263502B2 (en) * 2012-05-18 2018-02-08 Otago Innovation Limited Combination treatments and compositions for wound healing
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2019170820A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
HRP20221110T1 (hr) * 2020-05-08 2022-11-25 Aicuris Gmbh & Co. Kg Parapoxvirus za kondicioniranje i liječenje infekcija uzrokovanih koronavirusom
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0886679B1 (de) * 1996-02-28 2007-06-06 Bayer HealthCare AG Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
DK0885013T3 (da) * 1996-04-15 2001-11-05 Anton Prof Dr Med Vet Dr Mayr Anvendelse af multipotente paramunitetsinducere fra svækkede, ikke-immunogene poxvirus eller parapoxvirus til fremstilling af lægemidler
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
SI21122A (sl) * 2000-07-11 2003-08-31 Bayer Aktiengesellschaft Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku

Also Published As

Publication number Publication date
PT1765370E (pt) 2009-09-23
DE602005016552D1 (de) 2009-10-22
WO2006005529A1 (en) 2006-01-19
EP1765370B1 (de) 2009-09-09
HK1097467A1 (en) 2007-06-29
US8343478B2 (en) 2013-01-01
EP1765370A1 (de) 2007-03-28
DK1765370T3 (da) 2009-11-02
PL1765370T3 (pl) 2010-02-26
CA2573204C (en) 2011-09-20
JP4897677B2 (ja) 2012-03-14
BRPI0513321B1 (pt) 2022-03-08
CN103800382A (zh) 2014-05-21
BRPI0513321A (pt) 2008-05-06
US20100255032A1 (en) 2010-10-07
CN1984666A (zh) 2007-06-20
ES2330540T3 (es) 2009-12-11
CA2573204A1 (en) 2006-01-19
JP2008505952A (ja) 2008-02-28

Similar Documents

Publication Publication Date Title
EA200700243A1 (ru) Способы лечения гепатита с
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
TW200510343A (en) Substituted dihydroquinazolines
DE60216151D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
ATE494373T2 (de) Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
DE602006015861D1 (de) Antivirale verbindungen
ATE486634T1 (de) Caspase 3, 8, 9 oder 10 inhibitoren in kombination mit mek inhibitoren zur behandlung von influenza
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
SE0300034D0 (sv) Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals
EA200602289A1 (ru) Применение иматиниба для лечения нарушений работы печени и вирусных инфекций
WO2004065406A3 (en) Rantes-derived peptides with anti-hiv activity
SG170825A1 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
MX2024010673A (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos.
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
WO2007002172A3 (en) Hiv-1 protease inhibitors
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
MX2022012987A (es) Metodos de tratamiento de infecciones virales usando arginasa.
UA90477C2 (ru) Способ лечения гепатита с (варианты)
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
MXPA05007901A (es) Terapia de combinacion para hcv.
EA202092732A1 (ru) АНТИТЕЛА, КОТОРЫЕ НАЦЕЛЕНЫ НА ГЛИКОПРОТЕИН gp120 ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ATE393768T1 (de) Nukleosidanaloga mit antiviraler wirkung
HK1155638A (en) Use of pegylated type iii interferons for the treatment of hepatitis c

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1765370

Country of ref document: EP